Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. more
Time Frame | DSGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.59% | -3.39% | 0.2% |
1-Month Return | 8.51% | -1.92% | 2.72% |
3-Month Return | 8.32% | -10.54% | 7.31% |
6-Month Return | 63.61% | -4.47% | 10.44% |
1-Year Return | 139.46% | 4.06% | 27.53% |
3-Year Return | -61.8% | 0.94% | 30.88% |
5-Year Return | -84.94% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 834.00K | 226.00 | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.65K | 5.00K | 129.00K | 466.00K | 537.00K | [{"date":"2019-12-31","value":0.31,"profit":true},{"date":"2020-12-31","value":0.93,"profit":true},{"date":"2021-12-31","value":24.02,"profit":true},{"date":"2022-12-31","value":86.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (820.00) | (4.77K) | (129.00K) | (466.00K) | (537.00K) | [{"date":"2019-12-31","value":-82000,"profit":false},{"date":"2020-12-31","value":-477400,"profit":false},{"date":"2021-12-31","value":-12900000,"profit":false},{"date":"2022-12-31","value":-46600000,"profit":false},{"date":"2023-12-31","value":-53700000,"profit":false}] |
Gross Margin | (0.10%) | (2112.39%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":-0.1,"profit":false},{"date":"2020-12-31","value":-2112.39,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 1.91M | 8.33M | 35.83M | 67.59M | 78.19M | [{"date":"2019-12-31","value":2.44,"profit":true},{"date":"2020-12-31","value":10.65,"profit":true},{"date":"2021-12-31","value":45.83,"profit":true},{"date":"2022-12-31","value":86.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (1.91M) | (8.33M) | (35.83M) | (67.59M) | (78.19M) | [{"date":"2019-12-31","value":-190800000,"profit":false},{"date":"2020-12-31","value":-833000000,"profit":false},{"date":"2021-12-31","value":-3583100000,"profit":false},{"date":"2022-12-31","value":-6759300000,"profit":false},{"date":"2023-12-31","value":-7819000000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (2.05M) | (8.28M) | (35.53M) | (63.31M) | (66.86M) | [{"date":"2019-12-31","value":-204700000,"profit":false},{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-6330800000,"profit":false},{"date":"2023-12-31","value":-6686200000,"profit":false}] |
Income Taxes | 139.00K | (201.30K) | (107.56K) | (4.69M) | (1.00) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-144.82,"profit":false},{"date":"2021-12-31","value":-77.38,"profit":false},{"date":"2022-12-31","value":-3374.82,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (2.05M) | (8.28M) | (35.53M) | (63.31M) | (72.36M) | [{"date":"2019-12-31","value":-204700000,"profit":false},{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-6330800000,"profit":false},{"date":"2023-12-31","value":-7236000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.05M) | (8.28M) | (35.53M) | (58.62M) | (66.86M) | [{"date":"2019-12-31","value":-204700000,"profit":false},{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-5861700000,"profit":false},{"date":"2023-12-31","value":-6686200000,"profit":false}] |
EPS (Diluted) | - | - | (0.86) | (1.14) | (1.20) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-86,"profit":false},{"date":"2022-12-31","value":-114,"profit":false},{"date":"2023-12-31","value":-120,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DSGN | |
---|---|
Cash Ratio | 34.19 |
Current Ratio | 34.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DSGN | |
---|---|
ROA (LTM) | -13.54% |
ROE (LTM) | -17.78% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DSGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DSGN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 22642.01 |
P/B | 1.40 |
Price/FCF | NM |
EV/R | 11004.35 |
EV/Ebitda | NM |
Design Therapeutics Inc (DSGN) share price today is $6.335
Yes, Indians can buy shares of Design Therapeutics Inc (DSGN) on Vested. To buy Design Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DSGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Design Therapeutics Inc (DSGN) via the Vested app. You can start investing in Design Therapeutics Inc (DSGN) with a minimum investment of $1.
You can invest in shares of Design Therapeutics Inc (DSGN) via Vested in three simple steps:
The 52-week high price of Design Therapeutics Inc (DSGN) is $7.77. The 52-week low price of Design Therapeutics Inc (DSGN) is $2.25.
The price-to-earnings (P/E) ratio of Design Therapeutics Inc (DSGN) is
The price-to-book (P/B) ratio of Design Therapeutics Inc (DSGN) is 1.40
The dividend yield of Design Therapeutics Inc (DSGN) is 0.00%
The market capitalization of Design Therapeutics Inc (DSGN) is $353.88M
The stock symbol (or ticker) of Design Therapeutics Inc is DSGN